Clinical Trials Logo
  1. Home
  2. EBV Infection
  3. NCT04084626

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

EBV Infection Clinical Trial

Official title:
A Clinical Trial of Programmed Cell Death Protein 1(PD1) Antibody and Lenalidomide as a Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis or Chronic Active EBV Infection(CAEBV)

Clinical Trial Summary

The present study was a prospective one-arm clinical study, in which EBV-HLH/chronic active EBV infection patients were selected as the main subjects to evaluate the effect of PD-1 antibody and lenalidomide regimens on ebv-dna and safety.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04084626
Study type Interventional
Source Beijing Friendship Hospital
Contact jingshi wang
Phone 86-010-63139862
Email wangjingshi987@126.com
Status Recruiting
Phase Phase 3
Start date September 15, 2019
Completion date July 1, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT00711035 - Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) Phase 1/Phase 2
Not yet recruiting NCT06075927 - Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT Phase 1/Phase 2
Recruiting NCT05039580 - Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy Phase 4
Recruiting NCT04782674 - Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related Diseases
Active, not recruiting NCT03475212 - Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Recruiting NCT03159364 - Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections Phase 1/Phase 2
Not yet recruiting NCT04690036 - PD-1 Antibody for Reactive EBV After BMT Early Phase 1
Recruiting NCT03491605 - Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
Recruiting NCT04189835 - EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Recruiting NCT04308278 - Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection Phase 4
Recruiting NCT05682703 - A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
Completed NCT05604378 - Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis
Recruiting NCT04832607 - Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections Phase 3
Recruiting NCT06135922 - Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection Phase 1
No longer available NCT01945619 - Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH) N/A